Featured Research

from universities, journals, and other organizations

Childhood cancer survivors show sustained benefit from common ADHD medication

Date:
September 14, 2010
Source:
St. Jude Children's Research Hospital
Summary:
A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial.

A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital investigators.

Researchers reported that one year after starting the drug methylphenidate, young cancer survivors scored better on tests of sustained attention and other measures of attention, social skills and behavior than did a similar group of unmedicated survivors. While taking methylphenidate, scores on the attention and behavior measures of many survivors returned to normal ranges. Methylphenidate is marketed under several brand names, including Ritalin and Concerta. The study is the first to document that some survivors enjoy long-term benefits from its use.

Coupled with results from earlier medication side effects studies, the study's authors said these findings offer hope and reassurance for survivors, their families and others looking for ways to ease such late effects of cancer and its treatment. The work appears in the September 13 online edition of the Journal of Clinical Oncology.

"We found that methylphenidate improves both attention and social skills and that these benefits are maintained," said Heather Conklin, Ph.D., assistant member of the St. Jude Department of Psychology and the study's first author. "Although the drug did not lead to a significant gain in measured academic skills, many parents reported their children's grades improved because the children did a better job of managing tasks like planning ahead for projects or remembering to complete and turn in assignments."

The results come as the growing ranks of childhood cancer survivors have the pediatric cancer community searching for better ways to ease or even prevent treatment late effects.

Conklin said the findings also underscore the need for non-pharmacological approaches. Earlier research from Conklin and her colleagues found only about half of young cancer survivors benefit from methylphenidate. Also, Conklin said many parents are reluctant to use the drug and some survivors may not be good candidates due to medical or other reasons. "We are moving forward with research into new strategies to benefit more survivors and their families," she said.

This study focused on young survivors of brain tumors and acute lymphoblastic leukemia (ALL). Their cancer treatment included surgery, radiation and/or chemotherapy targeting the central nervous system. Those treatments and other factors, including a patient's age at treatment, are linked to risk of later attention, memory and processing speed problems that make learning difficult. Such troubles can reverberate through life and affect a survivor's ability to hold a job and live independently.

Although methylphenidate has been used successfully for decades to treat ADHD in healthy children, Conklin said that was no guarantee the drug would benefit children whose symptoms followed a cancer diagnosis. Excluded from this study were children who had ADHD before their cancer was found.

After a year of methylphenidate, young cancer survivors scored better on tests of sustained attention. Parent, teacher and survivor ratings of attention all improved. Parental ratings of social skills and behavior problems also documented that survivors had benefited. The group included 35 brain tumor and 33 ALL survivors.

In contrast, only parental ratings of attention and social skills improved during the same period for a similar group of survivors not taking medication. The group included 31 brain tumor and 23 ALL survivors.

Academic skills measured by completion of math, reading and spelling problems were not significantly better in either group. Conklin said that might reflect the study design, which did not assess changes in executive aspects of school performance, including organization and planning.

The other authors of this paper are Wilburn Reddick, Jason Ashford, Susan Ogg, Scott Howard, Robbin Christensen, Shengjie Wu, Xiaoping Xiong (St. Jude); E. Brannon Morris (Athens, Ga.); Ronald Brown (Temple University); Melanie Bonner (Duke University) and Raja Khan (Semmes-Murphey Institute, Memphis).

This work was supported in part by the National Cancer Institute and ALSAC.


Story Source:

The above story is based on materials provided by St. Jude Children's Research Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Heather M. Conklin, Wilburn E. Reddick, Jason Ashford, Susan Ogg, Scott C. Howard, E. Brannon Morris, Ronald Brown, Melanie Bonner, Robbin Christensen, Shengjie Wu, Xiaoping Xiong, Raja B. Khan. Long-Term Efficacy of Methylphenidate in Enhancing Attention Regulation, Social Skills, and Academic Abilities of Childhood Cancer Survivors. Journal of Clinical Oncology, 2010; DOI: 10.1200/JCO.2010.28.4026

Cite This Page:

St. Jude Children's Research Hospital. "Childhood cancer survivors show sustained benefit from common ADHD medication." ScienceDaily. ScienceDaily, 14 September 2010. <www.sciencedaily.com/releases/2010/09/100913172410.htm>.
St. Jude Children's Research Hospital. (2010, September 14). Childhood cancer survivors show sustained benefit from common ADHD medication. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2010/09/100913172410.htm
St. Jude Children's Research Hospital. "Childhood cancer survivors show sustained benefit from common ADHD medication." ScienceDaily. www.sciencedaily.com/releases/2010/09/100913172410.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins